Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Related Keywords

Joaquim Bellmunt ,Genitourinary Oncology Program ,Guidelines Committee ,Bladder Cancer Center ,Dana Farber Cancer Institute ,Harvard Medical School ,Patients With Metastatic Urothelial Cancer ,Enfortumab Vedotin ,Nivolumab ,Pembrolizumab ,Cisplatin Based Chemotherapy ,Ev 302 ,Checkmate 901 ,